The Chemours Company

Quarterly Financial Information

February 16, 2018

Safe Harbor Statement

This presentation contains forward-looking statements, within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical or current fact. The words "believe," "expect," “will,” "anticipate," "plan," "estimate," "target," "project" and similar expressions, among others, generally identify "forward-looking statements," which speak only as of the date such statements were made. These forward-looking statements may address, among other things, the outcome or resolution of any pending or future environmental liabilities, the commencement, outcome or resolution of any regulatory inquiry, investigation or proceeding, the initiation, outcome or settlement of any litigation, changes in environmental regulations in the U.S. or other jurisdictions that affect demand for or adoption of our products, anticipated future operating and financial performance, business plans and prospects, capital investments and projects, plans for dividends or share repurchases, sufficiency or longevity of intellectual property protection, cost savings targets, plans to increase profitability and growth, our ability to make acquisitions, integrate acquired businesses or assets into our operations, and achieve anticipated synergies or cost savings, and our outlook for net sales, Adjusted EBITDA, Adjusted EPS, Free Cash Flow, and Return on Invested Capital, all of which are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Forward-looking statements are based on certain assumptions and expectations of future events that may not be accurate or realized. These statements are not guarantees of future performance. Forward-looking statements also involve risks and uncertainties that are beyond Chemours' control. Additionally, there may be other risks and uncertainties that Chemours is unable to identify at this time or that Chemours does not currently expect to have a material impact on its business. Factors that could cause or contribute to these differences include the risks, uncertainties and other factors discussed in our filings with the U.S. Securities and Exchange Commission, including in our Annual Report on Form 10-K for the year ended December 31, 2017. Chemours assumes no obligation to revise or update any forward-looking statement for any reason, except as required by law.

Non-GAAP Financial Measures

We prepare our financial statements in accordance with Generally Accepted Accounting Principles (“GAAP”). Within this presentation, we may make reference to Adjusted Net Income (Loss), Adjusted EPS, Adjusted EBITDA, Adjusted EBITDA margin, Free Cash Flow, Return on Invested Capital (ROIC) and Net Leverage Ratio which are non-GAAP financial measures. The company includes these non-GAAP financial measures because management believes they are useful to investors in that they provide for greater transparency with respect to supplemental information used by management in its financial and operational decision making.

Management uses Adjusted Net Income (Loss), Adjusted EPS, Adjusted EBITDA, Adjusted EBITDA margin, Free Cash Flow, ROIC and Net Leverage Ratio to evaluate the company’s performance excluding the impact of certain noncash charges and other special items which we expect to be infrequent in occurrence in order to have comparable financial results to analyze changes in our underlying business from quarter to quarter.

Accordingly, the company believes the presentation of these non-GAAP financial measures, when used in conjunction with GAAP financial measures, is a useful financial analysis tool that can assist investors in assessing the company’s operating performance and underlying prospects. This analysis should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. This analysis, as well as the other information in this press release, should be read in conjunction with the company’s financial statements and footnotes contained in the documents that the company files with the U.S. Securities and Exchange Commission. The non-GAAP financial measures used by the company in this press release may be different from the methods used by other companies. For more information on the non-GAAP financial measures, please refer to the attached schedules or the table, “Reconciliation of Non-GAAP Financial Measures to GAAP Financial Measures” and materials posted to the company’s website at investors.chemours.com.

CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

(Dollars in millions, except per share amounts)

	Full Year 2017	4Q17	3Q17	2Q17	1Q17	Full Year 2016	4Q16	3Q16	2Q16	1Q16	Full Year 2015	4Q15	3Q15	2Q15	1Q15	Full Year 2014
Net sales	**$ 6,183**	$ 1,575	$ 1,584	$ 1,588	$ 1,437	**$ 5,400**	$ 1,322	$ 1,398	$ 1,383	$ 1,297	**$ 5,717**	$ 1,360	$ 1,486	$ 1,508	$ 1,363	**$ 6,432**
Cost of goods sold	**4,429**	1,087	1,117	1,147	1,079	**4,290**	1,023	1,056	1,116	1,095	**4,762**	1,147	1,222	1,282	1,111	**5,072**
Gross profit	**1,754**	488	467	441	358	**1,110**	299	342	267	202	**955**	213	264	226	252	**1,360**
Selling, general and administrative expense	**602**	158	148	152	144	**934**	480	148	174	133	**632**	151	157	157	167	**685**
Research and development expense	**80**	20	20	21	19	**80**	20	19	17	23	**97**	29	18	27	23	**143**
Restructuring and asset-related charges, net	**57**	26	8	11	12	**170**	25	60	67	17	**333**	88	184	61	-	**21**
Goodwill impairment	**-**	-	-	-	-	**-**	-	-	-	-	**25**	-	25	-	-	**-**
Total expenses	**739**	204	176	184	175	**1,184**	525	227	258	173	**1,087**	268	384	245	190	**849**
Equity in earnings of affiliates	**33**	7	9	10	7	**29**	12	9	4	5	**22**	4	7	8	3	**20**
Interest expense, net	**(215)**	(54)	(55)	(55)	(51)	**(213)**	(56)	(51)	(50)	(57)	**(132)**	(53)	(51)	(28)	-	**-**
Other income (expense), net	**79**	27	5	13	34	**247**	(3)	161	(4)	93	**54**	(17)	57	21	(7)	**19**
Income (loss) before income taxes	**912**	264	250	225	173	**(11)**	(273)	234	(41)	70	**(188)**	(121)	(107)	(18)	58	**550**
Provision for (benefit from) income taxes	**165**	36	43	64	22	**(18)**	(43)	30	(23)	19	**(98)**	(35)	(78)	-	15	**149**
Net income (loss)	**747**	228	207	161	151	**7**	(230)	204	(18)	51	**(90)**	(86)	(29)	(18)	43	**401**
Less: Net income attributable to non-controlling interests	**1**	-	-	-	1	**-**	-	-	-	-	**-**	-	-	-	-	**1**
Net income (loss) attributable to Chemours	**$ 746**	$ 228	$ 207	$ 161	$ 150	**$ 7**	$ (230)	$ 204	$ (18)	$ 51	**$ (90)**	$ (86)	$ (29)	$ (18)	$ 43	**$ 400**
Per share data																
Basic earnings (loss) per share of common stock (1)	**$ 4.04**	$ 1.23	$ 1.12	$ 0.87	$ 0.82	**$ 0.04**	$ (1.26)	$ 1.12	$ (0.10)	$ 0.28	**$ (0.50)**	$ (0.48)	$ (0.16)	$ (0.10)	$ 0.24	**$ 2.21**
Diluted earnings (loss) per share of common stock (1)	**$ 3.91**	$ 1.19	$ 1.08	$ 0.84	$ 0.79	**$ 0.04**	$ (1.26)	$ 1.11	$ (0.10)	$ 0.28	**$ (0.50)**	$ (0.48)	$ (0.16)	$ (0.10)	$ 0.24	**$ 2.21**
Dividends per share of common stock (1)	**$ 0.29**	$ 0.20	$ 0.03	$ 0.03	$ 0.03	**$ 0.12**	$ 0.03	$ 0.03	$ 0.03	$ 0.03	**$ 0.58**	$ 0.03	$ 0.03	$ 0.55	$ -	**$ -**

(1) On July 1, 2015, E.I. du Pont de Nemours and Company distributed 180,966,833 shares of Chemours' common stock to holders of its common stock. Basic and diluted earnings (loss) per common share and dividends per common share for the periods on or prior to June 30, 2015 were calculated using the number of shares distributed on July 1, 2015.

* Note: Summation of individual quarters may not sum to the year-to-date (YTD) or full year amounts due to rounding.

CONSOLIDATED BALANCE SHEETS
(Dollars in millions, except per share amounts)

	December 31, 2017	December 31, 2016	December 31, 2015
Assets			
Current assets:			
Cash and cash equivalents	$ 1,556	$ 902	$ 366
Accounts and notes receivable - trade, net	919	807	859
Inventories	935	767	972
Prepaid expenses and other	83	77	104
Total current assets	3,493	2,553	2,301
Property, plant and equipment	8,511	7,997	9,015
Less: Accumulated depreciation	(5,503)	(5,213)	(5,838)
Property, plant and equipment, net	3,008	2,784	3,177
Goodwill and other intangible assets, net	166	170	176
Investments in affiliates	173	136	136
Other assets	453	417	508
Total assets	$ 7,293	$ 6,060	$ 6,298
Liabilities and equity			
Current liabilities:			
Accounts payable	$ 1,075	$ 884	$ 973
Current maturities of long-term debt	15	15	39
Other accrued liabilities	558	872	454
Total current liabilities	1,648	1,771	1,466
Long-term debt, net	4,097	3,529	3,915
Deferred income taxes	208	132	234
Other liabilities	475	524	553
Total liabilities	6,428	5,956	6,168
Commitments and contingent liabilities			
Equity			
Common stock (par value $0.01 per share; 810,000,000 shares authorized)	2	2	2
Treasury stock at cost	(116)	-	-
Additional paid-in capital	837	789	775
Retained earnings (accumulated deficit)	579	(114)	(115)
Accumulated other comprehensive loss	(442)	(577)	(536)
Total Chemours stockholders' equity	860	100	126
Non-controlling interests	5	4	4
Total equity	865	104	130
Total liabilities and equity	$ 7,293	$ 6,060	$ 6,298

SEGMENT NET SALES (UNAUDITED)
(Dollars in millions)

	LTM 4Q17	Full Year 2017	4Q17	3Q17	2Q17	1Q17	Full Year 2016	4Q16	3Q16	2Q16	1Q16	Full Year 2015	4Q15	3Q15	2Q15	1Q15	Full Year 2014
Titanium Technologies	**$ 2,958**	**$ 2,958**	$ 785	$ 799	$ 729	$ 646	**$ 2,364**	$ 623	$ 625	$ 596	$ 521	**$ 2,392**	$ 589	$ 616	$ 642	$ 545	**$ 2,937**
Fluoroproducts	**2,654**	**2,654**	656	637	710	652	**2,264**	569	591	573	531	**2,230**	515	575	588	552	**2,327**
Chemical Solutions	**571**	**571**	134	148	149	139	**772**	130	182	214	245	**1,095**	256	295	278	266	**1,168**
TOTAL CHEMOURS	**$ 6,183**	**$ 6,183**	$ 1,575	$ 1,584	$ 1,588	$ 1,437	**$ 5,400**	$ 1,322	$ 1,398	$ 1,383	$ 1,297	**$ 5,717**	$ 1,360	$ 1,486	$ 1,508	$ 1,363	**$ 6,432**

SEGMENT ADJUSTED EBITDA (UNAUDITED)
(Dollars in millions)

	LTM 4Q17	Full Year 2017	4Q17	3Q17	2Q17	1Q17	Full Year 2016	4Q16	3Q16	2Q16	1Q16	Full Year 2015	4Q15	3Q15	2Q15	1Q15	Full Year 2014
Titanium Technologies	**$ 862**	**$ 862**	$ 261	$ 249	$ 193	$ 159	**$ 466**	$ 157	$ 144	$ 111	$ 54	**$ 326**	$ 62	$ 80	$ 91	$ 93	**$ 723**
Fluoroproducts	**669**	**669**	159	158	197	155	**445**	111	143	105	85	**300**	80	91	54	75	**282**
Chemical Solutions	**57**	**57**	20	18	7	12	**39**	9	9	11	10	**29**	16	8	4	1	**17**
Corporate and Other	**(166)**	**(166)**	(46)	(44)	(36)	(41)	**(128)**	(38)	(28)	(40)	(21)	**(82)**	(26)	(10)	(22)	(24)	**(146)**
TOTAL CHEMOURS	**$ 1,422**	**$ 1,422**	$ 394	$ 381	$ 361	$ 285	**$ 822**	$ 239	$ 268	$ 187	$ 128	**$ 573**	$ 132	$ 169	$ 127	$ 145	**$ 876**

SEGMENT ADJUSTED EBITDA MARGIN (UNAUDITED)

	LTM 4Q17	Full Year 2017	4Q17	3Q17	2Q17	1Q17	Full Year 2016	4Q16	3Q16	2Q16	1Q16	Full Year 2015	4Q15	3Q15	2Q15	1Q15	Full Year 2014
Titanium Technologies	**29.1%**	**29.1%**	33.2%	31.2%	26.5%	24.6%	**19.7%**	25.2%	23.0%	18.6%	10.4%	**13.6%**	10.5%	13.0%	14.2%	17.1%	**24.6%**
Fluoroproducts	**25.2%**	**25.2%**	24.2%	24.8%	27.7%	23.8%	**19.7%**	19.5%	24.2%	18.3%	16.0%	**13.5%**	15.5%	15.8%	9.2%	13.6%	**12.1%**
Chemical Solutions	**10.0%**	**10.0%**	14.9%	12.2%	4.7%	8.6%	**5.1%**	6.9%	4.9%	5.1%	4.1%	**2.6%**	6.3%	2.7%	1.4%	0.4%	**1.5%**
Corporate and Other	**0.0%**	**0.0%**	0.0%	0.0%	0.0%	0.0%	**0.0%**	0.0%	0.0%	0.0%	0.0%	**0.0%**	0.0%	0.0%	0.0%	0.0%	**0.0%**
TOTAL CHEMOURS	**23.0%**	**23.0%**	25.0%	24.1%	22.7%	19.8%	**15.2%**	18.1%	19.2%	13.5%	9.9%	**10.0%**	9.7%	11.4%	8.4%	10.6%	**13.6%**

* Note summation of individual quarters may not sum to the year-to-date (YTD), last twelve months (LTM) or full year amounts due to rounding.

SEGMENT NET ASSETS
(Dollars in millions)

	Full Year 2017	Full Year 2016	Full Year 2015	Full Year 2014
Titanium Technologies	$ 1,785	$ 1,513	$ 1,659	$ 1,748
Fluoroproducts	1,842	1,400	1,567	1,480
Chemical Solutions (1)	460	292	839	782
Corporate and Other	(3,222)	(3,101)	(3,935)	(337)
TOTAL CHEMOURS	$ 865	$ 104	$ 130	$ 3,673

(1) As of December 31, 2016, Chemical Solutions' net assets were reduced by approximately $415 in connection with the sales of our Clean & Disinfect and Sulfur businesses during 2016. For further details, refer to Note 7 of the Consolidated Financial Statements included in our Annual Report on Form 10-K as of and for the year ended December 31, 2017.

Chemours

RECONCILIATION OF NON-GAAP MEASURES (UNAUDITED)

(Dollars in millions, except per share amounts)

ADJUSTED NET INCOME AND ADJUSTED EBITDA

	LTM* 4Q17	Full Year 2017	4Q17	3Q17	2Q17	1Q17	Full Year 2016	4Q16	3Q16	2Q16	1Q16	Full Year 2015	4Q15	3Q15	2Q15	1Q15	Full Year 2014
Net income (loss) attributable to Chemours	**$ 746**	$ 746	$ 228	$ 207	$ 161	$ 150	**$ 7**	$ (230)	$ 204	$ (18)	$ 51	**$ (90)**	$ (86)	$ (29)	$ (18)	$ 43	**$ 400**
Non-operating pension and other post-retirement employee benefit (income) costs	**(34)**	(34)	(10)	(7)	(10)	(8)	**(20)**	(1)	(5)	(7)	(7)	**(3)**	(8)	(10)	8	7	**22**
Exchange (gains) losses	**(3)**	(3)	-	4	(2)	(5)	**57**	20	17	14	6	**(19)**	28	(44)	(19)	16	**66**
Restructuring charges	**57**	57	26	8	11	12	**51**	11	14	9	17	**285**	85	139	61	-	**21**
Asset-related charges (1)	**3**	3	-	1	2	-	**124**	14	46	63	-	**73**	3	70	-	-	**-**
(Gain) loss on sale of assets or business (2)	**(22)**	(22)	(8)	-	2	(16)	**(254)**	3	(169)	1	(89)	**9**	9	-	-	-	**(40)**
Transaction costs (3)	**3**	3	-	1	2	-	**19**	1	2	12	3	**9**	9	-	-	-	**-**
Legal and other charges (4)	**18**	18	-	7	5	7	**359**	336	5	13	5	**8**	8	-	-	-	**-**
Adjustments made to income taxes (5, 7)	**(25)**	(25)	(3)	(11)	(2)	(10)	**18**	18	-	-	-	**-**	-	-	-	-	**-**
(Benefit from) provision for income taxes relating to reconciling items (6, 7)	**(14)**	(14)	(4)	(5)	(5)	1	**(148)**	(139)	(5)	(5)	1	**(129)**	(46)	(53)	(15)	(14)	**(16)**
Adjusted Net Income	**$ 729**	$ 729	$ 229	$ 205	$ 164	$ 131	**$ 213**	$ 33	$ 109	$ 82	$ (13)	**$ 143**	$ 2	$ 73	$ 17	$ 52	**$ 453**
Net income attributable to non-controlling interests	**1**	1	-	-	-	1	**-**	-	-	-	-	**-**	-	-	-	-	**1**
Interest expense, net	**215**	215	54	55	55	51	**213**	56	51	50	57	**132**	53	51	28	-	**-**
Depreciation and amortization	**273**	273	69	62	71	71	**284**	72	73	73	66	**267**	66	70	67	64	**257**
All remaining provision for (benefit from) income taxes (7)	**204**	204	42	59	71	32	**112**	78	35	(18)	18	**31**	11	(25)	15	29	**165**
Adjusted EBITDA	**$ 1,422**	$ 1,422	$ 394	$ 381	$ 361	$ 285	**$ 822**	$ 239	$ 268	$ 187	$ 128	**$ 573**	$ 132	$ 169	$ 127	$ 145	**$ 876**
Adjusted earnings per share, basic	**$ 3.95**	$ 3.95	$ 1.23	$ 1.11	$ 0.89	$ 0.71	**$ 1.17**	$ 0.18	$ 0.60	$ 0.45	$ (0.07)	**$ 0.79**	$ 0.01	$ 0.40	$ 0.09	$ 0.29	**$ 2.50**
Adjusted earnings per share, diluted (8)	**$ 3.82**	$ 3.82	$ 1.19	$ 1.07	$ 0.86	$ 0.69	**$ 1.16**	$ 0.18	$ 0.59	$ 0.45	$ (0.07)	**$ 0.79**	$ 0.01	$ 0.40	$ 0.09	$ 0.29	**$ 2.50**

(1) The year ended December 31, 2016 includes pre-tax impairment charges of $13 million and $58 million associated with the sales of our corporate headquarters building located in Wilmington, Delaware and Sulfur business, respectively, and $48 million in pre-tax impairment charges associated with our aniline facility in Pascagoula, Mississippi, as well as certain other asset write-offs. The year ended December 31, 2015 includes pre-tax impairment charges of $45 million associated with our RMS facility in Niagara Falls, New York, and $25 million of goodwill impairment charges associated with our Sulfur business.

(2) The year ended December 31, 2017 includes gains of $13 million and $12 million associated with meeting certain milestones in connection with our sale of land in Repauno, New Jersey, and for the sale of our Edge Moor, Delaware plant site, respectively, net of certain losses on other disposals. The year ended December 31, 2016 includes gains of $169 million and $89 million associated with the sales of our C&D business and aniline facility in Beaumont, Texas, respectively.

(3) Includes accounting, legal, and bankers' transaction fees incurred related to our strategic initiatives, which includes pre-sale transaction costs incurred in connection with the sales of the C&D and Sulfur businesses during 2016.

(4) Includes litigation settlements, water treatment accruals, and lease termination charges. The year ended December 31, 2016 includes $335 million in litigation accruals associated with the PFOA MDL Settlement.

(5) Includes the removal of certain discrete income tax impacts within our provision for (benefit from) income taxes. For 2017, the adjustment is primarily attributable to a benefit of $20 million related to windfall benefits on our share-based payments, the reversal of a reserve for uncertain tax positions of $6 million, and a benefit for the net impact of U.S. tax reform of $3 million, which are partially offset by foreign exchange gains and losses of $5 million. For 2016, the adjustment of $18 million related entirely to tax implications of foreign exchange gains and losses. Adjustments have not been made to 2015 due to the nature of the tax provision in the year of our Separation from DuPont.

(6) The income tax impacts included in this caption are determined using the applicable rates in the taxing jurisdictions in which income or expense occurred and include both current and deferred income tax (benefit) expense based on the nature of the non-GAAP performance measure.

(7) Total provision for (benefit from) income taxes reconciles to the amount reported in the consolidated statements of operations for the years ended December 31, 2017, 2016, and 2015.

(8) Diluted earnings per share is calculated using net income (loss) available to common shareholders divided by diluted weighted-average shares of common shares outstanding during each period, which includes unvested restricted shares. Diluted earnings per share considers the impact of potentially dilutive securities except in periods in which there is a loss because the inclusion of the potential common shares would have an anti-dilutive effect.

* Note summation of individual quarters may not sum to the year-to-date (YTD), last twelve months (LTM) or full year amounts due to rounding.

RECONCILIATION OF FREE CASH FLOW

	YTD 2017	4Q17	3Q17	2Q17	1Q17	Full Year 2016	4Q16	3Q16	2Q16	1Q16	Full Year 2015	4Q15	3Q15	2Q15	1Q15	Full Year 2014
Cash provided by (used for) operating activities	**$ 639**	$ 303	$ 112	$ 183	$ 41	**$ 594**	$ 269	$ 199	$ 90	$ 36	**$ 182**	$ 302	$ 113	$ 5	$ (238)	**$ 505**
Purchases of property, plant and equipment	**(411)**	(165)	(108)	(69)	(69)	**(338)**	(103)	(67)	(79)	(89)	**(519)**	(127)	(105)	(150)	(137)	**(604)**
FREE CASH FLOW (1)	**$ 228**	$ 138	$ 4	$ 114	$ (28)	**$ 256**	$ 166	$ 132	$ 11	$ (53)	**$ (337)**	$ 175	$ 8	$ (145)	$ (375)	**$ (99)**

(1) Cash flows provided by operating activities for the year ended December 31, 2017 include $335 million in payments related to the PFOA MDL Settlement. Cash flows provided by operating activities for the year ended December 31, 2016 include $190 million in prepayments from DuPont, of which, $58 million was outstanding at December 31, 2016. The DuPont prepayment was fully utilized during the year ended December 31, 2017.

* Note summation of individual quarters may not sum to the year-to-date (YTD), last twelve months (LTM) or full year amounts due to rounding.

ADJUSTED NET INCOME AND ADJUSTED EBITDA RECONCILIATING ITEMS BY CATEGORY (UNAUDITED)

(Dollars in millions)

Reconciling Items	S/Ops Category	COGS					SG&A and Restructuring					Total				
		Full Year * 2017	4Q17	3Q17	2Q17	1Q17	Full Year * 2017	4Q17	3Q17	2Q17	1Q17	Full Year * 2017	4Q17	3Q17	2Q17	1Q17
Non-operating pension and other postretirement employee benefit income	COGS/SG& (1)	$ (10)	$ (3)	$ (2)	$ (3)	$ (2)	$ (24)	$ (7)	$ (5)	$ (7)	$ (6)	$ (34)	$ (10)	$ (7)	$ (10)	$ (8)
Exchange gains	OIE (2)	-	-	-	-	-	-	-	-	-	-	(3)	-	4	(2)	(5)
Restructuring charges	Restructuring (3)	-	-	-	-	-	57	26	8	11	12	57	26	8	11	12
Asset-related charges	COGS (1) / Restructuring (3)	2	-	-	2	-	-	-	-	-	-	3	-	1	2	-
(Gain) loss on sale of assets or business	OIE (2)	-	-	-	-	-	-	-	-	-	-	(22)	(8)	-	2	(16)
Transaction costs	SG&A (1)	-	-	-	-	-	1	-	1	-	-	3	-	1	2	-
Legal and other charges	SG&A (1)	-	-	-	-	-	19	-	7	5	7	18	-	7	5	7
Adjustments made to income taxes	Income tax	-	-	-	-	-	-	-	-	-	-	(25)	(3)	(11)	(2)	(10)
(Benefit from) provision for income taxes relating to reconciling items	Income tax	-	-	-	-	-	-	-	-	-	-	(14)	(4)	(5)	(5)	1
Total Adjusted Net Income reconciling items		$ (8)	$ (3)	$ (2)	$ (1)	$ (2)	$ 53	$ 19	$ 11	$ 9	$ 13	$ (17)	$ 1	$ (2)	$ 3	$ (19)
Net income attributable to non-controlling interests		-	-	-	-	-	-	-	-	-	-	1	-	-	-	1
Interest expense, net	Interest Expense	-	-	-	-	-	-	-	-	-	-	215	54	55	55	51
Depreciation and amortization	COGS/SG&A (1)	245	62	56	64	63	28	7	6	7	8	273	69	62	71	71
All remaining provision for income taxes	Income tax	-	-	-	-	-	-	-	-	-	-	204	42	59	71	32
Total Adjusted EBITDA reconciling items		$ 237	$ 59	$ 54	$ 63	$ 61	$ 81	$ 26	$ 17	$ 16	$ 21	$ 676	$ 166	$ 174	$ 200	$ 136

(1) COGS and SG&A represent the "cost of goods sold" and "selling, general and administrative expense" lines of the statements of operations, respectively.
(2) OIE represents the "other income (expense), net" line of the statements of operations.
(3) Restructuring represents the "restructuring and asset-related charges, net" line of the statements of operations.

* Note summation of individual quarters may not sum to the year-to-date (YTD), last twelve months (LTM) or full year amounts due to rounding.

RETURN ON INVESTED CAPITAL (UNAUDITED)
(Dollars in millions)

	Year Ended December 31,	
	2017	**2016**
Adjusted EBITDA (1)	$ 1,422	$ 822
Less: Depreciation and amortization	(273)	(284)
Adjusted EBIT	1,149	538
Total debt	4,112	3,544
Total equity	865	104
Less: Cash and cash equivalents	(1,556)	(902)
Invested capital, net	$ 3,421	$ 2,746
Average invested capital (2)	$ 3,157	$ 3,419
Return on Invested Capital	36.4%	15.7%

(1) See a reconciliation of Adjusted EBITDA to net income (loss) attributable to Chemours in preceding tab.

(2) Average invested capital is based on a five-point trailing average of invested capital, net.